BioCentury
ARTICLE | Clinical News

Antibe's pain candidate meets in Phase IIb GI safety trial

March 30, 2018 5:47 PM UTC

Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF) reported data from a double-blind, Canadian Phase IIb trial in 244 healthy volunteers undergoing gastroduodenal endoscopies showing that pain candidate ATB-346 for 14 days met the primary endpoint of improved GI safety vs. naproxen. Once-daily 250 mg oral ATB-346 led to a significantly lower incidence of gastric or duodenal ulcers of at least 3 mm diameter after 14 days of treatment vs. naproxen (2.5% vs. 42.1%, p<0.001). ATB-346 was well tolerated...

BCIQ Company Profiles

Antibe Therapeutics Inc.

BCIQ Target Profiles

COX-2

Cyclooxygenase-1 (COX-1)